Bertoni Natália, Pereira Lied M S, Severino Fábio E, Moura Regina, Yoshida Winston B, Reis Patricia P
Department of Surgery and Orthopedics, Faculty of Medicine, São Paulo State University-UNESP, Av. Prof. Montenegro, 18618-970, Botucatu, São Paulo, Brazil.
BMC Med Genet. 2016 Jan 15;17:4. doi: 10.1186/s12881-015-0262-2.
Hemangioma is a common benign tumor in the childhood; however our knowledge about the molecular mechanisms of hemangioma development and progression are still limited. Currently, microRNAs (miRNAs) have been shown as gene expression regulators with an important role in disease pathogenesis. Our goals were to identify miRNA-mRNA expression networks associated with infantile hemangioma.
We performed a meta-analysis of previously published gene expression datasets including 98 hemangioma samples. Deregulated genes were further used to identify microRNAs as potential regulators of gene expression in infantile hemangioma. Data were integrated using bioinformatics methods, and genes were mapped in proteins, which were then used to construct protein-protein interaction networks.
Deregulated genes play roles in cell growth and differentiation, cell signaling, angiogenesis and vasculogenesis. Regulatory networks identified included microRNAs miR-9, miR-939 and let-7 family; these microRNAs showed the most number of interactions with deregulated genes in infantile hemangioma, suggesting that they may have an important role in the molecular mechanisms of disease. Additionally, results were used to identify drug-gene interactions and druggable gene categories using Drug-Gene Interaction Database. We show that microRNAs and microRNA-target genes may be useful biomarkers for the development of novel therapeutic strategies for patients with infantile hemangioma.
microRNA-regulated pathways may play a role in infantile hemangioma development and progression and may be potentially useful for future development of novel therapeutic strategies for patients with infantile hemangioma.
血管瘤是儿童期常见的良性肿瘤;然而,我们对血管瘤发生和发展的分子机制的了解仍然有限。目前,微小RNA(miRNA)已被证明是基因表达调节剂,在疾病发病机制中起重要作用。我们的目标是识别与婴儿血管瘤相关的miRNA- mRNA表达网络。
我们对先前发表的包括98个血管瘤样本的基因表达数据集进行了荟萃分析。失调基因进一步用于识别作为婴儿血管瘤基因表达潜在调节因子的微小RNA。使用生物信息学方法整合数据,并将基因映射到蛋白质中,然后用于构建蛋白质-蛋白质相互作用网络。
失调基因在细胞生长和分化、细胞信号传导、血管生成和血管发生中起作用。鉴定出的调控网络包括微小RNA miR-9、miR-939和let-7家族;这些微小RNA在婴儿血管瘤中与失调基因的相互作用最多,表明它们可能在疾病的分子机制中起重要作用。此外,利用药物-基因相互作用数据库的结果来识别药物-基因相互作用和可成药基因类别。我们表明,微小RNA和微小RNA靶基因可能是开发婴儿血管瘤患者新治疗策略的有用生物标志物。
微小RNA调节的途径可能在婴儿血管瘤的发生和发展中起作用,并且可能对未来开发婴儿血管瘤患者的新治疗策略具有潜在用途。